Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06881537 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 18, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with Bevacizumab plus Anti-PD1 Antibody as neoadjuvant therapy for locally recurrent colorectal cancer
Trial Details
NCT Number NCT06881537
Lead Sponsor Shanghai Changzheng Hospital
Conditions
(from sponsor)		 Locally Recurrent Colorectal Cancer
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov